OpenAI buys Orchestra and its AI-powered platform supporting drug developers

On Tuesday, OpenAI moved further into drug development by buying Orchestra Bio. OpenAI plans to combine its collection of AI models and tools for life sciences research with Orchestra's platform, which helps drug companies organize and manage their drug development work.

The purchase comes about six months after OpenAI introduced GPT-Rosalind, an advanced AI model designed to help with drug discovery. It helps scientists work through questions about biology and chemistry. OpenAI's Rosalind family of tools also includes Rosalind Workbench. This tool connects the AI model to tools that researchers can use to study their data and plan experiments.

Orchestra's platform focuses more on helping drug developers organize and simplify their work. Users can ask AI agents to watch and track studies. This allows people to focus on important decisions and deal with problems the platform finds.

OpenAI said one possible use for Orchestra's technology is when a drug company's manufacturing batch fails. Orchestra's AI agents can help find out which activities and schedules are affected, gather information about the failure, and analyze possible ways for the team to respond.

By combining Orchestra's technology with Rosalind, OpenAI aims to "help scientists make discoveries and manage the work needed to turn them into treatments that reach patients sooner." This includes building AI agents that can connect research findings with the "studies, decisions, and next steps needed to advance a potential medicine."

OpenAI has announced several partnerships with drug developers, including Sanofi, Novo and Moderna.